Core Points - Bavarian Nordic A/S has initiated two clinical trials for the MVA-BN mpox/smallpox vaccine targeting vulnerable populations, specifically infants under 2 years and pregnant or breastfeeding women [1][2] - The first study involves 344 infants aged 4-24 months, while the second study aims to enroll 359 women [1][2] - Both studies are conducted in the Democratic Republic of Congo, the epicenter of the ongoing mpox outbreak [1] - Bavarian Nordic is also sponsoring a trial for children aged 2-11 years, with topline results expected in Q3 2025 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines and is a preferred supplier of mpox and smallpox vaccines to governments [5] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in several countries, including the U.S., Canada, and the EU [4] - The vaccine was originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure supply for the entire population, including immunocompromised individuals [4]

TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding C ...